<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778982</url>
  </required_header>
  <id_info>
    <org_study_id>KN026-205</org_study_id>
    <nct_id>NCT04778982</nct_id>
  </id_info>
  <brief_title>Study of KN026 in Combination With Palbociclib With or Without Fulvestrant in Patients With Advanced HER2-positive Breast Cancer</brief_title>
  <official_title>A Phase Ib/II, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With Palbociclib With or Without Fulvestrant in Patients With Locally Advanced Unresectable or Metastatic HER2-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, dose-escalation and parallel-group expansion Phase Ib/II&#xD;
      clinical trial to evaluate the efficacy, safety and tolerability of KN026 in combination with&#xD;
      palbociclib with or without fulvestrant in women or male with HER2-positive metastatic breast&#xD;
      cancer .The subjects will receive 20 mg/kg IV Q2W+ palbociclib 100/125 mg/day&#xD;
      orally+/-Fulvestrant 500 mg IM until progressive disease, unacceptable toxicity or death.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping&#xD;
      epitopes of HER2, leading to a dual HER2 signal blockade.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The proportion of patients experiencing dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>ORR as assessed by the investigator according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>clinical response time (DOR) as determined by investigators based on RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) rates</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Progression free survival (PFS) rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Overall survival (OS) rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>CBR calculated as the proportion of subjects with best overall response of CR, PR, or SD ≥24 weeks</time_frame>
    <description>Clinical benefit rate</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">66</enrollment>
  <condition>HER2-positive Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>dose-escalation Phase</arm_group_label>
    <description>KN026 20 mg/kg + palbociclib 100 /125 mg/day (Patients with HR-/HER2-positive MBC) or KN026 20 mg/kg + palbociclib 100 /125 mg/day+Fulvestrant 500 mg (Patients with HR+/HER2-positive MBC )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>parallel-group expansion Phase</arm_group_label>
    <description>KN026 20 mg/kg + palbociclib RP2D(Patients with HR-/HER2-positive MBC ) or KN026 20 mg/kg + palbociclib RP2D+Fulvestrant 500 mg(Patients with HR+/HER2-positive MBC )</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN026 combined with Palbociclib</intervention_name>
    <description>HR-/HER2-positive MBC will be treated by KN026 20 mg/kg and Palbociclib RP2D</description>
    <arm_group_label>dose-escalation Phase</arm_group_label>
    <other_name>KN026 combination therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN026 combined with Palbociclib and Fulvestrant</intervention_name>
    <description>HR+/HER2-positive MBC will be treated by KN026 20 mg/kg and Palbociclib RP2D+fulvestrant 500 mg</description>
    <arm_group_label>parallel-group expansion Phase</arm_group_label>
    <other_name>combination</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      ctDNA and single cell sequencing analysis may be performed using plasma samples collected&#xD;
      from subjects at baseline and upon disease progression.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        diagnosing locally advanced unresectable or metastatic HER2-positive&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject &gt;= 18 years;&#xD;
&#xD;
          -  Histologically or cytologically confirmed, metastatic or locally advanced unresectable&#xD;
             HER2-positive;&#xD;
&#xD;
          -  Adequate organ function assessed within 7 days prior to first trial treatment&#xD;
&#xD;
          -  ECOG score 0 or 1;&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50% at baseline;&#xD;
&#xD;
          -  Life expectancy &gt;3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated active CNS metastasis or leptomeningeal metastasis;&#xD;
&#xD;
          -  Uncontrolled tumor-related pain;&#xD;
&#xD;
          -  Has received other anti-tumor treatment or an investigational drug within 28 days or&#xD;
             within 5 times of half-life (whichever is shorter, and no less than 2 weeks) prior to&#xD;
             the first trial treatment;&#xD;
&#xD;
          -  Major surgery for any reason within 28 days;&#xD;
&#xD;
          -  Curative radiation within 3 months of the first dose of trial treatment;&#xD;
&#xD;
          -  History of uncontrolled intercurrent illness;&#xD;
&#xD;
          -  Other medical conditions that at the discretion of investigator interfere with the&#xD;
             requirements of the trial in terms of safety or efficacy evaluation, or treatment&#xD;
             compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiong Wu, professor</last_name>
    <phone>13601637369</phone>
    <email>wujiong1122@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Zhang, professor</last_name>
    <phone>18017312991</phone>
    <email>syner2000@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KN026</keyword>
  <keyword>palbociclib</keyword>
  <keyword>HER2-positive MBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

